Immunic to Participate in Investor and Scientific Conferences in September

Company Overview - Immunic, Inc. is a biotechnology company focused on developing orally administered small molecule therapies for chronic inflammatory and autoimmune diseases [6] - The lead development program, vidofludimus calcium (IMU-838), is in phase 3 clinical trials for treating relapsing multiple sclerosis, with top-line data expected by the end of 2026 [6] - Vidofludimus calcium has shown therapeutic activity in phase 2 trials for both relapsing-remitting and progressive multiple sclerosis [6] Upcoming Conferences - Immunic will participate in several investor and scientific conferences in September 2025, including the H.C. Wainwright 27th Annual Global Investment Conference from September 8-10, where company executives will present an overview and hold one-on-one meetings [1] - The company will also attend the Leerink Partners Biopharma Summit from September 17-19, and the 41st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) from September 24-26, where data on vidofludimus calcium will be presented [5] Presentation Details - At ECTRIMS, Immunic will present data on vidofludimus calcium, including an oral presentation and four poster presentations, one of which is a late-breaking poster [5] - Key presentations will include efficacy and safety data from the Phase 2 CALLIPER Trial for progressive multiple sclerosis, with specific sessions scheduled for September 24, 2025 [5][6]